Arena
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients
Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity
Obesity affects approximately 15 million people in the UK
Eisai submits new drug application for subcutaneous Leqembi in Japan
LEQEMBI is a treatment for early Alzheimer’s disease
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment
The MHRA approval for IV dosing comes following positive results from the global phase 3 trial
Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial
The company is planning to submit the candidate for regulatory review by the end of the year
Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years
An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership
The companies will launch four development programmes for potential small molecule therapies